By KATIE THOMAS and SHEILA KAPLAN
Long untouchable, the incentive for development of orphan drugs is now a Republican target as lawmakers consider a broad tax overhaul.
Published: November 7, 2017 at 07:00PM
from NYT Health http://ift.tt/2zpkko8
via IFTTT
from WordPress http://ift.tt/2hVqWk9
via IFTTT
No comments:
Post a Comment